Overview

* Illumina ( ILMN ) Q3 revenue of $1.08 bln beats analyst expectations

* Adjusted EPS of $1.34 for Q3 beats consensus estimates

* Company repurchased 1.2 mln shares for $120 mln

Outlook

* Company expects FY25 constant currency revenue decline of (1.5%) to (0.5%)

* Illumina ( ILMN ) raises FY25 non-GAAP EPS guidance to $4.65 - $4.75

* Company anticipates FY25 non-GAAP operating margin of 22.75% to 23%

Result Drivers

* CLINICAL MARKET GROWTH - Revenue acceleration driven by growth in clinical market, Illumina's ( ILMN ) largest segment, per CEO Jacob Thaysen

* EX-CHINA GROWTH - Company returned to growth outside of China, executing on strategic pillars for long-term targets

* NEW TECHNOLOGIES - Launched 5-base solution and Constellation mapped read technology, enhancing genomic insights

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.08 $1.07

Revenue bln bln (16

Analysts

)

Q3 Beat $1.34 $1.16

Adjusted (18

EPS Analysts

)

Q3 EPS $0.98

Q3 Beat $206 mln $181.62

Adjusted mln (16

Net Analysts

Income )

Q3 Net $150 mln

Income

Q3 Gross 67.6%

Margin

Q3 24.5%

Adjusted

EBIT

Margin

Q3 69.2%

Adjusted

Gross

Margin

Q3 EBIT 21%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and 3 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Illumina Inc ( ILMN ) is $110.00, about 13.6% above its October 29 closing price of $95.03

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)